Nefecon

Dec 17, 2019

China IND Approval Triggers $5 Million Milestone Payment From Everest Medicines

Sep 03, 2019

Positive Feedback From FDA Significantly Benefits Ongoing NefIgArd Pivotal Phase 3 Study

Aug 15, 2019

Calliditas Therapeutics: Interim Report Q2, 2019

Jan 14, 2019

Calliditas Therapeutics Appoints Frank Bringstrup as VP Regulatory Affairs

Jan 08, 2019

Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America

Nov 13, 2018

First patient Enrolled in Pivotal Clinical Phase 3 Study NEFIGARD with Lead Candidate Nefecon

Oct 01, 2018

Presentation at International IgA Nephropathy Network Meeting Highlighting Supportive Post-hoc Analysis of the NEFIGAN Study